Minakem Header W48

Minakem Header W48

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

ReAlta Life Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

FDA Clears ReAlta Life Sciences’ Phase 2 STAR Trial of RLS-0071 in Neonates with Hypoxic-Ischemic Encephalopathy

Details:

RLS-0071 is the Company’s lead dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic-ischemic encephalopathy and other rare diseases.

Lead Product(s): RLS-0071

Therapeutic Area: Neurology Product Name: RLS-0071

Highest Development Status: Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2022

ASK
US

Upload
your Pipeline Activity

IXICO

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

IXICO Selected by Cyclerion for New Alzheimer's Disease Study

Details:

IXICO has been selected by Cyclerion Therapeutics, Inc., a new client, to support the company's Phase IIa clinical trial to investigate CY6463 for treatment of individuals with Alzheimer's disease.

Lead Product(s): CY6463

Therapeutic Area: Neurology Product Name: CY6463

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Cyclerion Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership March 02, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY